Intercept Pharmaceuticals, Inc.

NasdaqGS:ICPT Stock Report

Market Cap: US$794.7m

Intercept Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Intercept Pharmaceuticals has been growing earnings at an average annual rate of 22.4%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 8.3% per year.

Key information

22.4%

Earnings growth rate

26.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate8.3%
Return on equity-80.0%
Net Margin-18.1%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Intercept cuts debt further with deal to exchange convertible notes

Sep 02

Intercept reduces debt with repurchases of $327.9M convertible notes

Aug 19

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Aug 13

Intercept Pharma Q2 2022 Earnings Preview

Aug 02

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Jul 07

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

May 23

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Revenue & Expenses Breakdown

How Intercept Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ICPT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 23318-57212160
30 Jun 23306-159210163
31 Mar 23295-173196171
31 Dec 22286-175176177
30 Sep 22277-202168187
30 Jun 22266-115166187
31 Mar 22263-120170180
31 Dec 21261-136177183
30 Sep 21275-144200185
30 Jun 21288-193230189
31 Mar 21297-231279185
31 Dec 20234-273261189
30 Sep 20301-321356204
30 Jun 20283-339362216
31 Mar 20272-347339241
31 Dec 19252-345317243
30 Sep 19234-335295241
30 Jun 19219-314275229
31 Mar 19196-318270217
31 Dec 18180-309255207
30 Sep 18164-333265200
30 Jun 18159-341269198
31 Mar 18146-352271195
31 Dec 17131-360270190
30 Sep 17107-369268186
30 Jun 1771-385261175
31 Mar 1746-376239166
31 Dec 1625-413229154
30 Sep 1612-381210131
30 Jun 167-343181123
31 Mar 162-314157117
31 Dec 153-226119113
30 Sep 153-17371107
30 Jun 153-15855107
31 Mar 153-774294
31 Dec 142-2833580
30 Sep 142-2612766
30 Jun 142-2572147
31 Mar 142-3041637
31 Dec 132-681328
30 Sep 132-861123
30 Jun 132-61818
31 Mar 132-53718
31 Dec 122-46516

Quality Earnings: ICPT is currently unprofitable.

Growing Profit Margin: ICPT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Return on Equity

High ROE: ICPT has a negative Return on Equity (-79.99%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/09 20:30
End of Day Share Price 2023/11/07 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intercept Pharmaceuticals, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Geoffrey MeachamBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.